NLRP2 negatively regulates antiviral immunity by interacting with TBK1

被引:20
作者
Yang, Yanqing [1 ,3 ,4 ,5 ]
Lang, Xueting [3 ,4 ,5 ]
Sun, Song [3 ,4 ,5 ]
Gao, Chun [6 ]
Hu, Jianguo [1 ]
Ding, Shuqin [1 ]
Li, Jing [1 ]
Li, Yuyun [2 ]
Wang, Fengchao [1 ]
Gong, Tao [2 ,3 ,4 ,5 ]
机构
[1] Bengbu Med Coll, Affiliated Hosp 1, Dept Clin Lab, Bengbu 233004, Anhui, Peoples R China
[2] Bengbu Med Coll, Anhui Prov Key Lab Infect & Immun, Dept Lab Med, Bengbu, Anhui, Peoples R China
[3] Univ Sci & Technol China, Inst Immunol, Hefei, Anhui, Peoples R China
[4] Univ Sci & Technol China, Sch Life Sci, CAS Ctr Excellence Mol Cell Sci, CAS Key Lab Innate Immun & Chron Dis, Hefei, Anhui, Peoples R China
[5] Univ Sci & Technol China, Med Ctr, Hefei, Anhui, Peoples R China
[6] Linyi Peoples Hosp, Dept Anesthesiol, Surg Bldg, Linyi, Peoples R China
基金
中国国家自然科学基金;
关键词
Antiviral innate immunity; NLRP2; TBK1; Type I interferons; NF-KAPPA-B; I INTERFERON; PATHOGENESIS; INFLAMMATION; ACTIVATION; RECEPTORS; SURVIVAL; SUPPORT; CANCER;
D O I
10.1002/eji.201847589
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Nucleotide-binding oligomerization domain (NOD)-like receptors (NLRs) are intracellular pattern recognition receptors (PRRs) that regulate a variety of inflammatory and host defense responses. Unlike the well-established NLRs, the roles of NLRP2 are controversial and poorly defined. Here, we report that NLRP2 acts as a negative regulator of TANK-binding kinase 1 (TBK1)-mediated type I interferon (IFN) signaling. Mechanistically, NLRP2 interacted directly with TBK1, and this binding disrupted the interaction of TBK1 and interferon regulatory factor 3 (IRF3), which interfered with TBK1-induced IRF3 phosphorylation. IFNs induce a series of proteins that have well-known antiviral or immune-regulatory functions, and tight control of the IFN signaling cascade is critical for limiting tissue damage and preventing autoimmunity. Our studies indicate that the NLRP2-TBK1 axis may serve as an additional signaling cascade to maintain immune homeostasis in response to viral infection.
引用
收藏
页码:1817 / 1825
页数:9
相关论文
共 29 条
  • [1] Type I interferon in systemic lupus erythematosus and other autoimmune diseases
    Banchereau, Jacques
    Pascual, Virginia
    [J]. IMMUNITY, 2006, 25 (03) : 383 - 392
  • [2] Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
    Barbie, David A.
    Tamayo, Pablo
    Boehm, Jesse S.
    Kim, So Young
    Moody, Susan E.
    Dunn, Ian F.
    Schinzel, Anna C.
    Sandy, Peter
    Meylan, Etienne
    Scholl, Claudia
    Froehling, Stefan
    Chan, Edmond M.
    Sos, Martin L.
    Michel, Kathrin
    Mermel, Craig
    Silver, Serena J.
    Weir, Barbara A.
    Reiling, Jan H.
    Sheng, Qing
    Gupta, Piyush B.
    Wadlow, Raymond C.
    Le, Hanh
    Hoersch, Sebastian
    Wittner, Ben S.
    Ramaswamy, Sridhar
    Livingston, David M.
    Sabatini, David M.
    Meyerson, Matthew
    Thomas, Roman K.
    Lander, Eric S.
    Mesirov, Jill P.
    Root, David E.
    Gilliland, D. Gary
    Jacks, Tyler
    Hahn, William C.
    [J]. NATURE, 2009, 462 (7269) : 108 - U122
  • [3] PAN1/NALP2/PYPAF2, an inducible inflammatory mediator that regulates NF-κB and caspase-1 activation in macrophages
    Bruey, JM
    Bruey-Sedano, N
    Newman, R
    Chandler, S
    Stehlik, C
    Reed, JC
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (50) : 51897 - 51907
  • [4] TBK1 Promote Bladder Cancer Cell Proliferation and Migration via Akt Signaling
    Chen, Wei
    Luo, Kewang
    Ke, Zhiyi
    Kuai, Bin
    He, Shiyang
    Jiang, Wei
    Huang, Weiren
    Cai, Zhiming
    [J]. JOURNAL OF CANCER, 2017, 8 (10): : 1892 - 1899
  • [5] TBK1 Provides Context-Selective Support of the Activated AKT/mTOR Pathway in Lung Cancer
    Cooper, Jonathan M.
    Ou, Yi-Hung
    McMillan, Elizabeth A.
    Vaden, Rachel M.
    Zaman, Aubhishek
    Bodemann, Brian O.
    Makkar, Gurbani
    Posner, Bruce A.
    White, Michael A.
    [J]. CANCER RESEARCH, 2017, 77 (18) : 5077 - 5094
  • [6] NLRP4 negatively regulates type I interferon signaling by targeting the kinase TBK1 for degradation via the ubiquitin ligase DTX4
    Cui, Jun
    Li, Yinyin
    Zhu, Liang
    Liu, Dan
    Zhou Songyang
    Wang, Helen Y.
    Wang, Rong-Fu
    [J]. NATURE IMMUNOLOGY, 2012, 13 (04) : 387 - 395
  • [7] NLRC5 Negatively Regulates the NF-κB and Type I Interferon Signaling Pathways
    Cui, Jun
    Zhu, Liang
    Xia, Xiaojun
    Wang, Helen Y.
    Legras, Xavier
    Hong, Jun
    Ji, Jiabing
    Shen, Pingping
    Zheng, Shu
    Chen, Zhijian J.
    Wang, Rong-Fu
    [J]. CELL, 2010, 141 (03) : 483 - 496
  • [8] The Inflammasome NLRs in Immunity, Inflammation, and Associated Diseases
    Davis, Beckley K.
    Wen, Haitao
    Ting, Jenny P. -Y.
    [J]. ANNUAL REVIEW OF IMMUNOLOGY, VOL 29, 2011, 29 : 707 - 735
  • [9] TANK-binding kinase 1 (TBK1) controls cell survival through PAI-2/serpinB2 and transglutaminase 2
    Delhase, Mireille
    Kim, Soo-Youl
    Lee, Ho
    Naiki-Ito, Aya
    Chen, Yi
    Ahn, Eu-Ree
    Murata, Kazuhiro
    Kim, Se-Jin
    Lautsch, Norman
    Kobayashi, Koichi S.
    Shirai, Tomoyuki
    Karin, Michael
    Nakanishi, Makoto
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2012, 109 (04) : E177 - E186
  • [10] Immunomodulatory functions of type I interferons
    Gonzalez-Navajas, Jose M.
    Lee, Jongdae
    David, Michael
    Raz, Eyal
    [J]. NATURE REVIEWS IMMUNOLOGY, 2012, 12 (02) : 125 - 135